Pershing Square Capital
View Older Stories View More Recent Stories
-
Bill Ackman Says Valeant (VRX) Now 'Classic' Pershing Square Investment - CNBC
-
Valeant under criminal investigation over Philidor ties: WSJ
-
Big Valeant Pharma (VRX) Investors, Pershing Square's Ackman Met Ahead of Q2 Report -NYP
-
Have Valeant Pharma (VRX) Shareholders Finally Capitulated?
-
S&P Removes Pershing Square from CreditWatch Negative as Valeant (VRX) Stabilizes
-
Pershing Square laid off 8 non-senior employees - WSJ
-
Ackman releases new Herbalife video; stock climbs
-
Form 4 Valeant Pharmaceuticals For: Jun 09 Filed by: Pershing Square Capital Management, L.P.
-
Ackman's Pershing Square Updates on Valeant Pharma (VRX) Options Position
-
Form SC 13D/A Valeant Pharmaceuticals Filed by: Pershing Square Capital Management, L.P.
-
Valeant Pharma (VRX) Rejected Joint Takeda, TPG Takeover Approach - WSJ
-
Activist investor heavyweights form new lobbying arm
-
Ackman's Pershing Square's 13F Shows Increased Stake in Restaurant Brands (QSR), Valeant (VRX), Lowered Stake in Air Products (APD), Mondelez (MDLZ), More ...
-
Regulatory filings show which Valeant investors exited in first quarter
-
Following Perrigo's (PRGO) Q1 Results, Some Question Valeant's (VRX) New CEO Pick
-
Key player in Pershing Square's Valeant bet leaving firm
-
Ackman's Pershing Square seeks to sell Zoetis shares for $800 million: NYT
-
Bill Ackman to Sell $800M in Zoetis (ZTS) Stock - NYT
-
Ackman defends Valeant, hints at more changes
-
Pershing Square's Ackman pledges to ensure Valeant (VRX) won't hike drug prices again - Bloomberg
-
Bill Ackman, Pearson, Schiller Among Valeant's (VRX) Senate Hearing Wtnesses
-
Exclusive: Valeant calls in investment banks to weigh options - sources
-
Legg Mason's Miller Thinks Valeant (VRX) Stock Could Double, Has Been Buying Shares
-
S&P Downgrades Valeant Pharma (VRX) to 'B'; Notes Escalation in Near-Term Default Risk
-
Ackman Shoots Down Idea of Valeant (VRX) Unloading Bausch & Lomb
-
Valeant Pharma (VRX) Ramps to Session Highs
-
Pershing Square's Ackman Says Valeant (VRX) was Passive Holding Until Recent, Board Focused on CEO Search
-
Ackman to face investor grilling after record quarterly loss
-
Ackman's fund falls 7 percent in March, hurt by Valeant
-
Form SC 13D/A Valeant Pharmaceuticals Filed by: Pershing Square Capital Management, L.P.
-
Valeant CEO subpoenaed to testify before U.S. Senate panel
-
Senate's request for info from Ackman related to Valeant: source
-
Ackman Sees Confidence Restored in Valeant Pharma (VRX) After 10-K Filed, New Leadership Identified
-
Pershing Square cooperating with U.S. probe - Reuters
-
Valeant Pharma (VRX) Enters Information Sharing Agreement with Pershing Square
-
Form SC 13D/A Valeant Pharmaceuticals Filed by: Pershing Square Capital Management, L.P.
-
Ackman Skipping Sohn Investment Conference to Focus on Valeant (VRX)
-
Form SC 13D/A Valeant Pharmaceuticals Filed by: Pershing Square Capital Management, L.P.
-
Drugmaker Valeant CEO leaving as investor Ackman joins board
-
Valeant Pharma (VRX) to Replace CEO Pearson; Adds Bill Ackman to Board
-
Valeant Announces CEO Succession Plan And Changes To Board Of Directors; Provides Accounting And Financial Reporting Update
-
S&P says it may cut Ackman hedge fund's rating
-
S&P Places Pershing Square Ratings on CreditWatch Negative; Notes Drop in Performance (VRX)
-
Ackman Said to Add to Valeant Pharma (VRX) Stake - Chatter
-
Ackman's Pershing Square Said to Support Valeant Pharma (VRX) CEO Pearson; Wants More Oversight - Bloomberg
-
Valeant Pharma (VRX) Bounces Modestly Off Lows Following Ackman Letter
-
Streetinsider.com's Hot Lunchtime Reads 3/15: (FB) (CLF) (QTWW) (VRX) (ALR)
-
Ackman's Pershing Square Sends Letter to Investors Following Valeant's (VRX) Q4 Report, Updated Outlook
-
Ackman's Pershing Square Said Down $666M+ This Week on Valeant Pharma (VRX) Stake
-
Drugmaker Valeant faces debt default risk; shares plunge 50 percent

